Tissue Regenix Group (LON:TRX) posted its quarterly earnings results on Monday. The company reported GBX (1) (($0.01)) EPS for the quarter, topping the Zacks’ consensus estimate of GBX (1.30) (($0.02)) by GBX 0.30 ($0.00), Bloomberg Earnings reports. Tissue Regenix Group had a negative return on equity of 95.68% and a negative net margin of 346.29%. The company had revenue of GBX 5,230 billion for the quarter.
Tissue Regenix Group (LON TRX) opened at GBX 8 ($0.11) on Monday. Tissue Regenix Group has a twelve month low of GBX 5.62 ($0.08) and a twelve month high of GBX 16.93 ($0.23). The company has a market capitalization of $100.98 and a P/E ratio of -800.00.
TRADEMARK VIOLATION NOTICE: “Tissue Regenix Group (TRX) Issues Earnings Results, Beats Estimates By $0.30 EPS” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3301752/tissue-regenix-group-trx-issues-earnings-results-beats-estimates-by-0-30-eps.html.
Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient’s body.
Receive News & Ratings for Tissue Regenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group and related companies with MarketBeat.com's FREE daily email newsletter.